00. Elsevier Masson SAS. Tous droits réservés Gastroenterol Clin Biol 00;:- MÉSOTHÉLIOMES MALINS DU PÉRITOINE ARTICLE ORIGINAL Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery
The Oncologist Clinical Pharmacology Update on Chemotherapeutic Agents Utilized for Perioperative Intraperitoneal Chemotherapy PAUL H. SUGARBAKER, a JORGE TORRES MORA, b PABLO CARMIGNANI, a O. ANTHONY
Colorectal carcinoma is one of the most frequent cancers, and is the third leading cause of cancer-associated deaths worldwide [7]. Besides liver metastasis and regional lymph nodes metastasis, peritoneal carcinomatosis of colon cancer occurs in 12-20% of patients whose disease recurs [38, 39]. However, therapeutic effects of conventional treatments, such as surgical resection, chemotherapy and radiotherapy, are not very encouraging. Therefore, unremitting efforts were focused on developing novel therapeutic strategies. Data presented in this study showed that AAV-mediated delivery of hPEDF could prevent tumor growth and metastasis and prolong the survival time in murine CRPC model (Figure 4A to 4D).. Angiogenesis is essential to maintain tumor growth and metastasis, therefore antiangiogenic therapy is a feasible approach for cancer therapy. In recent years, a variety of angiogenesis inhibitors have been discovered, among which PEDF is the most promising one. Based on previous studies, ...
Prognosis and treatment is the same as for the most common type of ovarian cancer, which is epithelial ovarian cancer.[5][6] The median survival of primary peritoneal carcinomas is usually shorter by 2-6 months time when compared with serous ovarian cancer. Studies show median survival varies between 11.3-17.8 months. One study reported 19-40 month median survival (95% CI) with a 5-year survival of 26.5%.[citation needed] Elevated albumin levels have been associated with a more favorable prognosis.[7] ...
This primary peritoneal carcinoma survivor says cancer has always been a constant in her family. Even from an early age, she always knew she was at risk.
Peritoneal surface malignancy (PSM) is a clinical entity with an unfavourable prognosis, which characterizes the evolution of neoplastic diseases from the abdominal and/or pelvic organs and could also be the terminal stage of extra-abdominal tumors. Examples of diseases that can spread mainly within the peritoneal cavity are appendiceal tumors, ovarian cancer, colorectal cancer, abdominal sarcomatosis, gastric cancer and peritoneal mesothelioma. The locoregional therapy is defined as the combination of cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP). The rationale of this combined therapy for PSM is based on the natural history of this clinical entity that remains confined in the peritoneal cavity for most of its natural history. This pattern of spread would seem to indicate the potential usefulness of selectively increasing drug concentration in the tumour-bearing area by direct intraperitoneal chemotherapy instillation. This approach led to these outcomes: the ...
TY - JOUR. T1 - A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. AU - Yan, Tristan D.. AU - Black, Deborah. AU - Sugarbaker, Paul H.. AU - Zhu, Jacqui. AU - Yonemura, Yutaka. AU - Petrou, George. AU - Morris, David L.. PY - 2007/10. Y1 - 2007/10. N2 - Background: The purpose of this systematic review and meta-analysis was to determine the effectiveness and safety of adjuvant intraperitoneal chemotherapy for patients with locally advanced resectable gastric cancer. Methods: Studies eligible for this systematic review included those in which patients with gastric cancer were randomly assigned to receive surgery combined with intraperitoneal chemotherapy versus surgery without intraperitoneal chemotherapy. There were no language restrictions. After independent quality assessment and data extraction, data were pooled for meta-analysis. Results: Thirteen reports of randomized controlled trials (RCTs) were ...
Advanced ovarian cancer is characterized by peritoneal metastasis and the accumulation of ascites. Peritoneal metastasis of ovarian cancer is a major cause of the negative treatment outcome, as these metastases are resistant to most chemotherapy regimens. The aim of this study was to clarify aggressive pathology of peritoneal metastasis and examine the therapeutic efficacy of a liposomal agent in the model. A human cancer cell line ES-2 of ovarian clear cell carcinoma, known as a chemotherapy-resistant cancer, was cultured in nonadherent plate to form spheroid and single cell suspension was transplanted into mouse peritoneal cavity. The epidermal growth factor receptor (EGFR) pathways in the cellular aggregates were analyzed both spheroid and ascites. The pharmacokinetics and therapeutic efficacy of CPT-11 (45 mg/kg) and IHL-305 (45 mg/kg), an irinotecan-encapsulated liposome, were examined by intravenous administration. Established peritoneal metastasis model showed an accumulation of ascites. The
TY - JOUR. T1 - Could texture features from preoperative ct image be used for predicting occult peritoneal carcinomatosis in patients with advanced gastric cancer?. AU - Kim, Hae Young. AU - Kim, Young Hoon. AU - Yun, Gabin. AU - Chang, Won. AU - Lee, Yoon Jin. AU - Kim, Bohyoung. PY - 2018/3. Y1 - 2018/3. N2 - Purpose To retrospectively investigate whether texture features obtained from preoperative CT images of advanced gastric cancer (AGC) patients could be used for the prediction of occult peritoneal carcinomatosis (PC) detected during operation. Materials and methods 51 AGC patients with occult PC detected during operation from January 2009 to December 2012 were included as occult PC group. For the control group, other 51 AGC patients without evidence of distant metastasis including PC, and whose clinical T and N stage could be matched to those of the patients of the occult PC group, were selected from the period of January 2011 to July 2012. Each group was divided into test (n = 41) and ...
Correlation of preoperative magnetic resonance imaging of peritoneal carcinomatosis and clinical outcome after peritonectomy and HIPEC after 3 years of follow-up: preliminary ...
The meta-analysis of data from 53 studies including 6,885 patients with stage III-IV epithelial ovarian cancer who underwent cytoreductive surgery followed by cisplatin or carboplatin-based chemotherapy showed that percent maximal cytoreduction was an independent prognostic variable for survival (P ,0.001) [2]. Each 10% increase in maximal cytoreduction was associated with a 5.5% increase in median survival. It is noteworthy that median survival time was 23.0 months for patients who had maximal cytoreductive surgery rate of 25% or less compared to 36.8 months for those in which maximal cytoreductive surgery was achieved in more than 75% of cases. The present study confirms that optimal surgical cytoreduction is the most important prognostic factor for advanced epithelial ovarian cancer [2-5, 7, 10, 17]. All attempts should be made to achieve complete cytoreduction, but when this result is not achievable, the surgical goal should be al least a residual disease , 1 cm [7]. Optimal cytoreduction ...
RATIONALE: Drugs used in chemotherapy, such as leucovorin, fluorouracil, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether systemic chemotherapy is more effective with or without intraperitoneal chemohyperthermia in treating patients with peritoneal carcinomatosis from colorectal cancer.. PURPOSE: This randomized phase III trial is studying systemic chemotherapy to see how well it works compared with or without intraperitoneal chemohyperthermia in treating patients undergoing surgery for peritoneal carcinomatosis from colorectal cancer. ...
TY - JOUR. T1 - Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. AU - Matulonis, Ursula A.. AU - Sharma, Sudarshan. AU - Ghamande, Sharad A. AU - Gordon, Michael S.. AU - Del Prete, Salvatore A.. AU - Ray-Coquard, Isabelle. AU - Kutarska, Elzbieta. AU - Liu, Hua. AU - Fingert, Howard. AU - Zhou, Xiaofei. AU - Danaee, Hadi. AU - Schilder, Russell J.. PY - 2012/10/1. Y1 - 2012/10/1. N2 - Objectives: Aurora A kinase (AAK), a key mitotic regulator, is implicated in the pathogenesis of several tumors, including ovarian cancer. This single-arm phase II study assessed single-agent efficacy and safety of the investigational AAK inhibitor MLN8237 (alisertib), in patients with platinum-refractory or -resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Methods: Adult women with malignant, platinum-treated disease received ...
Abstract Cancer dissemination to peritoneal surfaces was, in the past, a lethal condition with a limited survival. Clinical and pharmacologic research have shown that options for b..
Inclusion Criteria: - Patients with a histologically confirmed diagnosis of high-grade nonmucinous epithelial ovarian (serous, endometrial, clear cell, carcinosarcoma, an mixed pathologies), fallopian tube, or primary peritoneal cancer that is Stage III or IV according to the International Federation of Gynecology and Obstetrics (FIGO) or tumor, node and metastasis staging criteria. - All patients with Stage IV disease are eligible. This includes those with inoperable disease, those who undergo primary debulking surgery (complete cytoreduction (CC0) or macroscopic disease), or those for whom neoadjuvant chemotherapy is planned. - Patients with Stage III are eligible if they meet one or more of the following criteria: 1. High risk Stage IIIC disease. 2. Planning to receive neoadjuvant chemotherapy. - Patients must provide a blood sample for research at Screening. - Patient must provide sufficient tumor tissue sample (a minimum of 2 formalin-fixed paraffin embedded blocks) at Screening for ...
OBJECTIVES: I. Compare pathological response, recurrence-free interval, and survival in patients with optimal stage III epithelial ovarian cancer or primary peritoneal carcinoma receiving intravenous (IV) paclitaxel and cisplatin vs IV paclitaxel and intraperitoneal (IP) cisplatin plus IP paclitaxel. II. Compare the toxic effects and complications of these 2 treatment regimens in these patients. III. Determine the frequency and prognostic significance of BRCA1 and BRCA2 mutations in these patients. IV. Determine the effect of non-genetic risk factors on the course of disease in BRCA1- and BRCA2-related ovarian cancer or primary peritoneal carcinoma. V. Compare the quality of life of these patients receiving these treatments.. OUTLINE: This is a randomized study. Patients are stratified according to gross residual disease (present vs absent) and whether second-look surgery will be performed at the end of treatment (yes vs no). Blood is drawn for BRCA mutation analysis and DNA extraction before ...
This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit organization that is leading Canadas national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. Designed by Educe Design & Innovation Inc. ...
Patients diagnosed with colon cancer are staged as stage IV (M1B) if they have peritoneal metastases. A poor survival rate (11%) 5 years overall survival has been found for this stage of colon cancer [9]. Even a more conservative figures of poor survival rates for this stage of colon cancer have been published (5 years survival rates of 0 % and median survival rate of 6-8 months) [10,11]. One of the major prognostic factors of survival in patients with colon cancer and peritoneal metastases is extent of disease, which is shown clearly in many research articles [12]. So its prudent to treat those patients with maximal cytoreduction in addition to other treatment options like neoadjuvant, and adjuvant chemotherapy and HIPEC [13].. From review of current literature it seemed that the best treatment options for these patients is to attempts systemic treatment ( either preoperative, postoperative chemotherapy , or both) as seen by Passot G [7], and Kuijpers A et al. [8], in both studies, patients ...
Peritoneal cancer affects the tissue that lines the abdominal cavity. Read this article to learn more about the symptoms and treatments for peritoneal cancer.
SPIS TREŚCI 2014, Tom XXXVI, Nr 216, CZERWIEC CONTENTS 2014, VOL XXXVI, No. 216, JUNE ARTYKUŁ REDAKCYJNY / EDITORIAL Chronowska J., Łabuzek K., Kukla U., Lekstan A., Okopień B.: 365 Dootrzewnowa chemioterapia perfuzyjna w hipertermii jako nowy sposób leczenia przerzutów nowotworowych do otrzewnej Hyperthermic intraperitoneal chemotherapy as a new way of peritoneal metastases treatment PRACE ORYGINALNE / ORIGINAL PAPERS Pawełczak E., Gaszyński T.: 369 Występowanie nadciśnienia tętniczego w społeczności miejskiej a promowanie zachowań prozdrowotnych The prevalence of hypertension among the urban community and promoting healthy behaviors Jerzykowska S., Cymerys M., Roszak M., Wysocka E., Michalak S., Pupek-Musialik D.: 373 Analiza wpływu krótkotrwałego wysiłku fizycznego na wybrane parametry funkcji śródbłonka naczyniowego oraz sztywność naczyń krwionośnych u młodych i zdrowych mężczyzn The analysis of the influence of short term physical effort on selected
Intraperitoneal chemotherapy is beneficial and tolerable, and physicians should present it as an option to women who have had successful cytoreductive surgery for their advanced epithelial ovarian cancer.
Peritoneal cancer is difficult to diagnose, especially because it often cannot be detected by radiological imaging. As a result, the incidence of peritoneal cancer has long been underestimated, and it was considered to be a very rare disease. Even today, the reported incidence rates of peritoneal cancer vary widely, but increasing awareness has led to increases in the reported incidence of peritoneal cancer in more recent studies. However, the "true" incidence is potentially higher because autopsy studies have found undetected peritoneal metastases in many cancer patients.. Malignant mesothelioma is a truly rare disease because it is diagnosed in approximately one to three patients per 1.000.000 persons per year. The disease is three times more common in men compared with women, and the risk of developing the disease increases with age. Malignant mesothelioma is mainly diagnosed in people who are 60 years and older, although younger patients have been described. The number of patients is ...
Despite progress in recent years towards the early detection of gastric cancer in the western country and Japan, most patients will already have advanced disease at diagnosis in our country. The majority of patients will die of recurrent disease, even if surgery is thought to be curative at the time.. Recent advances in preoperative diagnosis using ultrasonography or computed tomography provide much more information on peritoneal metastasis before operation. However, it is impossible to obtain information about small peritoneal metastasis preoperatively. Therefore, PWC must be performed in addition to macroscopic observation and palpation in patients with advanced gastric cancer. Therefore, cases positive for PWC are considered as peritoneal metastasis, according to the JCGC [10,11].. The prognostic value of positive cytology findings was recently confirmed also in the West, and a new stage classification for gastric carcinoma, recently published by Japanese Gastric Cancer Association, employs ...
... in the largest biology dictionary online. Free learning resources for students covering all major areas of biology.
Control of cellular metabolism is critical for efficient cell function, although little is known about the interplay between cell subset-specific metabolites in situ, especially in the tumor setting. Here, we determined how a macrophage-specific (Mϕ-specific) metabolite, itaconic acid, can regulate tumor progression in the peritoneum. We show that peritoneal tumors (B16 melanoma or ID8 ovarian carcinoma) elicited a fatty acid oxidation-mediated increase in oxidative phosphorylation (OXPHOS) and glycolysis in peritoneal tissue-resident macrophages (pResMϕ). Unbiased metabolomics identified itaconic acid, the product of immune-responsive gene 1-mediated (Irg1-mediated) catabolism of mitochondrial cis-aconitate, among the most highly upregulated metabolites in pResMϕ of tumor-bearing mice. Administration of lentivirally encoded Irg1 shRNA significantly reduced peritoneal tumors. This resulted in reductions in OXPHOS and OXPHOS-driven production of ROS in pResMϕ and ROS-mediated MAPK activation ...
The mucin MUC16 and the glycosylphosphatidylinositol anchored glycoprotein mesothelin likely facilitate the peritoneal metastasis of ovarian tumors. The biochemical basis and the kinetics of the binding between these two glycoproteins are not clearly understood. Here we have addressed this deficit and provide further evidence supporting the role of the MUC16-mesothelin interaction in facilitating cell-cell binding under conditions that mimic the peritoneal environment. In this study we utilize recombinant-Fc tagged human mesothelin to measure the binding kinetics of this glycoprotein to MUC16 expressed on the ovarian tumor cell line OVCAR-3. OVCAR-3 derived sublines that did not express MUC16 showed no affinity for mesothelin. In a flow cytometry-based assay mesothelin binds with very high affinity to the MUC16 on the OVCAR-3 cells with an apparent Kd of 5-10 nM. Maximum interaction occurs within 5 mins of incubation of the recombinant mesothelin with the OVCAR-3 cells and significant binding is
Although women with stage I ovarian SBT have excellent prognoses, with a disease-free survival rate approaching 100%, at least 25% of patients with stages II, III, and IV ovarian SBT suffer relapse, and at least 10% die of disease (2, 3, 4, 5, 6, 7, 8, 9, 10, 11) . These patients with stages II-IV SBT have peritoneal implants that are classified as either noninvasive or invasive. Noninvasive implants have an appearance similar to primary SBT. They are characterized by glandular or papillary proliferations with cell detachments; cellular atypia, psammoma bodies, and desmoplastic fibrosis may be present in some cases (2, 3, 4, 5, 6, 7, 8, 9 , 11) . Invasive peritoneal implants are lesions similar to noninvasive implants but with epithelial cells infiltrating the surrounding stroma, singly or in clusters. They are characterized by irregular penetration of the underlying tissue (2, 3, 4, 5, 6, 7, 8, 9, 10) . In our series (10 , 11) , invasive peritoneal implants were much less common than ...
Background: Peritoneal metastasis is a common and dismal evolution of several gastrointestinal (GI) tumors, including gastric, colorectal, hepatobiliary, pancreatic, and other cancers. The therapy of peritoneal metastasis is largely palliative; with the aim of prolonging life and preserving its quality. In the meantime, a significant pharmacological advantage of intraperitoneal chemotherapy was documented in the preclinical model, and numerous clinical studies have delivered promising clinical results. Methods: This is a prospective, open, randomized multicenter phase III clinical study with two arms that aims to evaluate the effects of pressurized intraperitoneal aerosol chemotherapy (PIPAC) combined with systemic chemotherapy vs. intravenous systemic chemotherapy alone on patients with metastatic upper GI tumors with a peritoneal seeding. Upper GI-adenocarcinomas originated from biliary tract, pancreas and stomach, or esophago- gastric junction are eligible. Patients in the study are treated ...
ConclusionsComplete CRS and HIPEC can be achieved in strictly selected patient with unresectable PM at diagnosis after repeated PIPAC session with palliative intent....
Ovarian carcinomas are chemosensitive tumors. Chemotherapy plays a pivotal role also in advanced disease, and the response to chemotherapy appears to be predictive of prolonged survival. Only performance status seems to limit therapy administration a
28 year old patient with history of gastric lesion proven to be gastric cancer underwent surgery 24 months ago, now presents with palpable hard abdominal mass with rapid increase of the abdominal size.CT of the abdomen and pelvis demonstrates mal...
FDA approves Keytruda for advanced melanoma: first PD-1 blocking drug to receive agency approval [press release]. Mucinous carcinoma of the skin, J Am Acad Dermatol ; It is caused by fluid secreted from a remnant piece of peritoneum wrapped around the testicle, called the tunica vaginalis.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may
Table 3: Pharmacokinetic parameters of paclitaxel (PAC) and docetaxel (DOC) in plasma and ascitic fluid after an i.p. administration of drugs in crEL or PS-80 to nontumor rats [18 ...
Well a bit later than planned, I can update you all on the Peritoneal Tumour Service Patient day at the Christie. I hope to meet more of you next time.
Array BioPharma announced results of a Phase 2 trial of selumetinib in women with recurrent low-grade serous ovarian or peritoneal cancer.
Information on this website is obtained from ClinicalTrials.gov. Using this information is subject to ClinicalTrials.govs Terms and Conditions ...
https://doi.org/10.18632/oncotarget.12383 Ting Yang, Qiaoxian Lin, Jinhua Ren, Ping Chen, Xiaohong Yuan, Xiaofeng Luo, Tingbo Liu, Jing Zheng, Zhihong Zheng, Xiaoyun Zheng, Xinji Chen, Langhui Zhang,...
It can be difficult to differentiate diffuse malignant peritoneal mesothelioma (DMPM) from reactive mesothelial hyperplasia (RMH) or peritoneal dissemination of gynecologic malignancies, such as epithelial ovarian cancer (EOC), which cause a large amount of ascites. Detection of the homozygous deletion of p16/CDKN2A (p16) by fluorescence in situ hybridization (FISH) is an effective adjunct in the diagnosis of malignant pleural mesothelioma. The aim of this study was to investigate the ability of the p16 FISH assay to differentiate DMPM from RMH and EOC.. ...
The imaging method called positron emission tomography (PET) using the radioactive tracer molecule 18F-FDG is a valuable way to both diagnose and track the progression of malignant peritoneal mesothelioma. Nuclear medicine researchers at a Hospital in Barcelona, Spain reviewed the diagnostic and treatment records of 60 people with malignant peritoneal mesothelioma, a form of mesothelioma that spreads on the membrane lining the walls of the abdomen. The study subjects included 34 women and 26 men with a mean age of 53. All the patients in the study had had multiple 18-F-FDG-PET scans to diagnose or track their cancer. Eleven of the studied patients had an FDG-PET scan prior to receiving treatment. In all cases, the scans showed characteristic mesothelioma disease … Continue reading Tracking Mesothelioma with FDG-PET » ...
To meet the needs of patients, Canadian surgical and medical oncology leaders in the treatment of peritoneal surface malignancies (psms), together with patient representatives, formed the Canadian HIPEC Collaborative Group (chicg). The group is dedicated to standardizing and improving the treatment of psm in Canada so that access to treatment and, ultimately, the prognosis of Canadian patients with psm are improved.. Patients with resectable psm arising from colorectal or appendiceal neoplasms should be reviewed by a multidisciplinary team including surgeons and medical oncologists with experience in treating patients with psm. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should be offered to appropriately selected patients and performed at experienced centres.. The aim of this publication is to present guidelines that we recommend be applied across the country for the treatment of psm.. ...
A review of 60 consecutive patients with peritoneal carcinomatosis who underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC)-sometimes called "hot chemotherapy"-found 0% mortality and 33% morbidity, with "a significant reduction of grade III/IV morbidity, perioperative transfusion, and reintervention rate after 20 procedures." Reporting their results in the Archives of Surgery,1 physicians at the Institut Paoli-Calmettes and Université de la Méditerranée in Marseille, France, noted that the "introduction of the HIPEC program was successful because of the surgical teams prior experience in cytoreductive and cancer operations.". Learning Curve. In an accompanying editorial, Nita Ahuja, MD, agreed: "The message that we can heed here is that experience matters." In a follow-up interview with The ASCO Post, Dr. Ahuja said that there are cytoreduction-with-HIPEC programs with experienced physicians at several centers in the United States (see sidebar). These ...
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is an appropriate treatment for select patients with peritoneal carcinomat
Given its rarity, there are no established guidelines for the treatment of peritoneal mesothelioma. The modern approach to malignant peritoneal mesothelioma includes cytoreductive surgery,[10] hyperthermic intraperitoneal chemotherapy (HIPEC), intraperitoneal chemotherapy, and intravenous chemotherapy.[11] These are often used in conjunction and in a complementary fashion, and this multifaceted approach has significantly improved outcomes when compared to intravenous chemotherapy alone. For instance, the reported median survival time for patients with stage IV mesothelioma as reported by the American Cancer Society is 12 months;[12] however, with adequate cytoreduction, intraperitoneal, and intravenous chemotherapy combined, some authors report 10-year survival rates projected at nearly 75%.[13]. Multiple factors have been shown to be significant in predicting the outcome and overall survival. Age greater than 60 at surgery, more overall disease burden (defined as a PCI greater than 15), ...
Abstract: Advancements in medical technology coupled with a more thorough comprehension of oncologic diseases has resulted in a burgeoning number of aggressive treatment options available to cancer patients and a gradual loosening of the association between cancer and timely death. With the advent of extended life expectancies, however, the need to investigate the human and overall life impact of cancer diseases and treatments has increased dramatically (Langenhoff et al., 2001). This need to examine considerations of quality of life becomes even more essential in the context of high-risk treatments, such as cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS+HIPEC), an extensive procedure offered to select candidates with peritoneal carcinomatosis from a variety of primary origins (Levine et al., 2007). A biopsychosocial model of research and clinical care (e.g. Wilson & Cleary, 1995) underscores the many levels and interrelationships of clinical, demographic, and ...
CASE REPORT: We present a case of low-grade appendiceal mucinous neoplasm with peritoneal dissemination, in which single-port laparoscopic approach of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy was completed through a 5.5-cm incision. A 35-year-old man with no medical illness underwent laparoscopic appendectomy for acute appendicitis 3 months earlier. Postoperative surgical pathology reported a low-grade appendiceal mucinous neoplasm with positive margin. After complete assessment and Tumor Board discussion, the patient was scheduled for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A single gel port access was inserted through a 5.5-cm peri-umbilical incision. The Peritoneal Cancer Index score was 4, and the decision was made to proceed with partial cecectomy, omentectomy, peritonectomy, and hyperthermic intraperitoneal chemotherapy with the Sugarbaker mitomycin C-based regimen. Postoperative care was carried out following the Enhanced Recovery ...
TY - JOUR. T1 - Localized malignant peritoneal mesothelioma arising in the mesentery of the ascending colon. AU - Kim, Younghye. AU - Lee, Eunjung. AU - Jung, Wonkyoung. AU - Kim, Han Kyeom. AU - Jung, Soon Hee. AU - Hong, Kwang Dae. AU - Lee, Youngseok. PY - 2012/5/1. Y1 - 2012/5/1. UR - http://www.scopus.com/inward/record.url?scp=84862862365&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84862862365&partnerID=8YFLogxK. M3 - Article. C2 - 22546096. AN - SCOPUS:84862862365. VL - 78. JO - American Surgeon. JF - American Surgeon. SN - 0003-1348. IS - 5. ER - ...
... , Hongwei Zhao, Na Liu, Dingxin Wang, Yuehong Yue, Bingjie Li, Xiaomeng Lang, Lili He, Qilu Hu, Ziqian Dun, Yesh
U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT03111069) titled Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children on April 6. Brief Summary: The goal of this clinical research study is to find the highest tolerable dose of heated doxorubicin that can be given to patients during surgery with abdominal tumors. The safety of this drug will also be studied. Study Start Date: Study Type: Interventional Condition: Malignant Neoplasms of Mesothelial and Soft Tissue Rhabdomyosarcoma, Pelvic Rhabdomyosarcoma, Abdominal Intervention: Procedure: Abdominal Surgery Resectable Intra-Abdominal/Pelvic Tumors Group: Participants receive peritonectomy, omentectomy, cytoreduction, (complete surgical tumor resection, no gross residual disease). Unresectable Intra-Abdominal/Pelvic Tumors Group: ...
BACKGROUND: Peritonectomy with heated intraperitoneal chemotherapy (HIPEC) has shown a survival benefit in selected patients with peritoneal carcinomatosis. This prospective non-randomized study was designed to identify factors associated with postoperative morbidity and survival after peritonectomy HIPEC in patients with this condition. METHOD: Data were prospectively collected from all patients with peritoneal carcinomatosis treated by means of peritonectomy and HIPEC at Uppsala University Hospital between October 2003 and September 2006. Depending on the primary tumor, mitomycin C or a platinum compound was used as a chemotherapeutic agent for perfusion. RESULTS: A total of 103 patients were treated. Primary tumors were pseudomyxoma peritonei (47 patients), colorectal cancer (38 patients), gastric cancer (6 patients), ovarian cancer (6 patients) and mesothelioma (5 patients). Postoperative morbidity was 56.3% and was significantly lower in patients treated with mitomycin C for pseudomyxoma ...